Publications
期刊发表
- Panda PK, Paschoalini Mafra AC, Bastos ACS, et al. BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. Clin Cancer Res. 2025;31(7):1333-1345. doi:10.1158/1078-0432.CCR-24-2548
- Carpentier J, Freitas M, Morales V, et al. Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma. iScience. 2024;28(1):111525. Published 2024 Dec 2. doi:10.1016/j.isci.2024.111525
- Abdelrahman AA, Sandow PV, Wang J, et al. Arginine deprivation/citrulline augmentation with ADI-PEG20 as novel therapy for complications in type 2 diabetes. Mol Metab. 2024;89:102020. doi:10.1016/j.molmet.2024.102020
- Du K, Grocott L, Anichini G, O’Neill K, Syed N. Amino Acid Deprivation in Glioblastoma: The Role in Survival and the Tumour Microenvironment-A Narrative Review. Biomedicines. 2024;12(11):2481. Published 2024 Oct 29. doi:10.3390/biomedicines12112481
- Vonderohe C, Stoll B, Didelija I, et al. Citrulline and ADI-PEG20 reduce inflammation in a juvenile porcine model of acute endotoxemia. Front Immunol. 2024;15:1400574. Published 2024 Aug 8. doi:10.3389/fimmu.2024.1400574
- Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789
- Rogers LC, Kremer JC, Brashears CB, et al. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment. Clin Cancer Res. 2023;29(16):3189-3202. doi:10.1158/1078-0432.CCR-22-2642
- Phillips MM, Pavlyk I, Allen M, et al. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma [published correction appears in Pharmacol Rep. 2023 Jun;75(3):753. doi: 10.1007/s43440-023-00487-z.]. Pharmacol Rep. 2023;75(3):570-584. doi:10.1007/s43440-023-00480-6
- Chu YD, Lai MW, Yeh CT. Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment. Int J Mol Sci. 2023;24(13):10668. Published 2023 Jun 26. doi:10.3390/ijms241310668
- Ye PH, Li CY, Cheng HY, et al. A novel combination therapy of arginine deiminase and an arginase inhibitor targeting arginine metabolism in the tumor and immune microenvironment. Am J Cancer Res. 2023;13(5):1952-1969. Published 2023 May 15.
- Barnett SE, Kenyani J, Tripari M, et al. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. Mol Cancer Res. 2023;21(5):411-427. doi:10.1158/1541-7786.MCR-22-0635
- Field GC, Pavlyk I, Szlosarek PW. Bench-to-Bedside Studies of Arginine Deprivation in Cancer. Molecules. 2023; 28(5):2150. https://doi.org/10.3390/molecules28052150
- Chu YD, Liu HF, Chen YC, Chou CH, Yeh CT. WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. Front Oncol. 2022;12:996820. Published 2022 Dec 2. doi:10.3389/fonc.2022.996820
- Zhang Y, DeBosch BJ. A protocol to induce systemic autophagy and increase energy metabolism in mice using PEGylated arginine deiminase. STAR Protoc. 2022;3(3):101489. doi:10.1016/j.xpro.2022.101489
- Carpentier J, Pavlyk I, Mukherjee U, Hall PE, Szlosarek PW. Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy. Lung Cancer (Auckl). 2022;13:53-66. Published 2022 Sep 5. doi:10.2147/LCTT.S335117
- Chan PY, Phillips MM, Ellis S, et al. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma. Pigment Cell Melanoma Res. 2022;35(4):461-470. doi:10.1111/pcmr.13042
- Szyszko TA., Dunn JT , Phillips MM, et al. Role of 3′-Deoxy-3′-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase. JTO Clinical and Research Reports, Volume 3, Issue 9, 2022, 100382, ISSN 2666-3643, https://doi.org/10.1016/j.jtocrr.2022.100382.
- Kraehenbuehl L, Holland A, Armstrong E, et al. Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers (Basel). 2022;14(11):2638. Published 2022 May 26. doi:10.3390/cancers14112638
- Hajji N, Garcia-Revilla J, Soto MS, et al. Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. J Clin Invest. 2022;132(6):e142137. doi:10.1172/JCI142137
- Zhang Y, Higgins CB, Van Tine BA, Bomalaski JS, DeBosch BJ. Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism. Cell Rep Med. 2022;3(1):100498. Published 2022 Jan 18. doi:10.1016/j.xcrm.2021.100498
- Yao S, Janku F, Koenig K, et al. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med. 2022;11(2):340-347. doi:10.1002/cam4.4446
- Harding JJ, Yang TS, Chen YY, et al. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. Cancer. 2021;127(24):4585-4593. doi:10.1002/cncr.33870
- Szlosarek PW, Wimalasingham AG, Phillips MM, et al. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer Med. 2021;10(19):6642-6652. doi:10.1002/cam4.4196
- Wu C, You M, Nguyen D, et al. Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma. Int J Mol Sci. 2021;22(14):7628. Published 2021 Jul 16. doi:10.3390/ijms22147628
- Chang KY, Chiang NJ, Wu SY, et al. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology. 2021;10(1):1943253. Published 2021 Jul 12. doi:10.1080/2162402X.2021.1943253
- Tsai HJ, Hsiao HH, Hsu YT, et al. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. Cancer Med. 2021;10(9):2946-2955. doi:10.1002/cam4.3871
- Yao S, Janku F, Subbiah V, et al. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021;124(9):1533-1539. doi:10.1038/s41416-020-01230-8
- Mohammad MA, Didelija IC, Stoll B, Nguyen TC, Marini JC. Pegylated arginine deiminase depletes plasma arginine but maintains tissue arginine availability in young pigs. Am J Physiol Endocrinol Metab. 2021;320(3):E641-E652. doi:10.1152/ajpendo.00472.2020
- Chu CY, Lee YC, Hsieh CH, et al. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy. Theranostics. 2021;11(8):3624-3641. Published 2021 Jan 25. doi:10.7150/thno.51795
- Rogers, L.C., Zhou, J., Baker, A. et al. Intracellular arginine-dependent translation sensor reveals the dynamics of arginine starvation response and resistance in ASS1-negative cells. Cancer Metab 9, 4 (2021). https://doi.org/10.1186/s40170-021-00238-9
- Kuo MT, Chen HHW, Feun LG, Savaraj N. Targeting the Proline-Glutamine-Asparagine-Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy. Pharmaceuticals (Basel). 2021;14(1):72. Published 2021 Jan 18. doi:10.3390/ph14010072
- Szlosarek PW, Phillips MM, Pavlyk I, et al. Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. JTO Clin Res Rep. 2020;1(4):100093. Published 2020 Sep 3. doi:10.1016/j.jtocrr.2020.100093
- Hall PE, Ready N, Johnston A, et al. Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer. Clin Lung Cancer. 2020;21(6):527-533. doi:10.1016/j.cllc.2020.07.012
- Brashears CB, Barlin M, Ehrhardt WR, et al. Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming. Cell Death Dis. 2020;11(8):662. Published 2020 Aug 20. doi:10.1038/s41419-020-02899-8
- Ji JX, Cochrane DR, Tessier-Cloutier B, et al. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Clin Cancer Res. 2020;26(16):4402-4413. doi:10.1158/1078-0432.CCR-19-1905
- Kuo MT, Long Y, Tsai WB, et al. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. Transl Oncol. 2020;13(2):355-364. doi:10.1016/j.tranon.2019.12.003
- Kim SS, Xu S, Cui J, et al. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics. 2020;10(2):829-840. Published 2020 Jan 1. doi:10.7150/thno.40195
研讨会发表
- Szlosarek PW, Pavlyk I, Carpentier J, et al. Translating arginine deprivation for uveal melanoma. PASPCR 2024 Annual Meeting, New York, NY. Pigment Cell Melanoma Res, 37: 693-712. https://doi.org/10.1111/pcmr.13191
- Ragon BK, Bomalaski J, Johnston A, et al. A Phase 1A/B Combination Study of Pegargiminase (ADI-PEG 20), Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia. The 65th ASH Annual Meeting Abstracts. Blood 2023; 142 (Supplement 1): 1554. doi: https://doi.org/10.1182/blood-2023-174954
- Yamatani K, Watanabe T, Saito K, et al. PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia. The 65th ASH Annual Meeting Abstracts. Blood 2023; 142 (Supplement 1): 4162. doi: https://doi.org/10.1182/blood-2023-178554
- Van Tine BA, Hirbe AC, Luo J, et al. Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma. 2021 ASCO Annual Meeting I, abstract 11508. JCO 39, 11508-11508(2021).DOI:10.1200/JCO.2021.39.15_suppl.11508